Antimicrobial Peptides SLPI and Beta Defensin-1 in Sputum are Negatively Correlated with FEV
antimicrobial peptide
chronic obstructive pulmonary disease
non-typeable haemophilus influenzae
Journal
International journal of chronic obstructive pulmonary disease
ISSN: 1178-2005
Titre abrégé: Int J Chron Obstruct Pulmon Dis
Pays: New Zealand
ID NLM: 101273481
Informations de publication
Date de publication:
Historique:
received:
13
01
2021
accepted:
19
04
2021
entrez:
7
6
2021
pubmed:
8
6
2021
medline:
28
7
2021
Statut:
epublish
Résumé
Chronic obstructive pulmonary disease (COPD) and asthma have heterogeneous inflammation with inhaled corticosteroids (ICS) as a mainstay of treatment. There is increased prevalence of non-typeable Secretory leukocyte protease inhibitor (SLPI), osteopontin, elafin and beta defensin-1 were measured in sputum supernatants from healthy donors (n=9), asthmatics (n=21) and patients with COPD (n=14). Elafin and beta defensin-1 were measured in a primary human bronchial epithelial cells (HBECs) from healthy and COPD donors infected with NTHi and pre-treated with fluticasone propionate (FP) and budesonide (BUD). Internalised NTHi was quantified by qPCR. Sputum SLPI was negatively correlated with FEV1 (p<0.001, r=-0.610), FEV1% predicted (p<0.001, r=-0.583) and FEV1/FVC (p=0.001, r=-0.528). Sputum beta defensin-1 was negatively associated with FEV1 (p<0.001***r=-0.594). SLPI and beta defensin-1 levels in sputum were higher in the healthy controls and COPD group compared to the asthma group (p=0.001 and p=0.014) and (p<0.001 and p=0.007, respectively). ICS use was associated with higher sputum osteopontin compared to those with no ICS use. NTHi infection of COPD HBECs produced higher levels of beta defensin-1 compared to healthy donors (mean (SD) release: 45.1pg/mL (7.3) vs 21.2pg/mL (7.3) respectively, p=0.014). Elafin release from HBECs from COPD donors did not change following NTHi infection; however, elafin from healthy donors was significantly reduced (%mean reduction: 23.7%, 95% confidence intervals (CI) of reduction: 5.3-38.4%, p<0.01). Sputum SLPI and beta defensin-1 may be markers to identify those patients with declining lung function. ICS use was associated with higher sputum osteopontin compared to those with no ICS use.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic obstructive pulmonary disease (COPD) and asthma have heterogeneous inflammation with inhaled corticosteroids (ICS) as a mainstay of treatment. There is increased prevalence of non-typeable
METHODS
METHODS
Secretory leukocyte protease inhibitor (SLPI), osteopontin, elafin and beta defensin-1 were measured in sputum supernatants from healthy donors (n=9), asthmatics (n=21) and patients with COPD (n=14). Elafin and beta defensin-1 were measured in a primary human bronchial epithelial cells (HBECs) from healthy and COPD donors infected with NTHi and pre-treated with fluticasone propionate (FP) and budesonide (BUD). Internalised NTHi was quantified by qPCR.
RESULTS
RESULTS
Sputum SLPI was negatively correlated with FEV1 (p<0.001, r=-0.610), FEV1% predicted (p<0.001, r=-0.583) and FEV1/FVC (p=0.001, r=-0.528). Sputum beta defensin-1 was negatively associated with FEV1 (p<0.001***r=-0.594). SLPI and beta defensin-1 levels in sputum were higher in the healthy controls and COPD group compared to the asthma group (p=0.001 and p=0.014) and (p<0.001 and p=0.007, respectively). ICS use was associated with higher sputum osteopontin compared to those with no ICS use. NTHi infection of COPD HBECs produced higher levels of beta defensin-1 compared to healthy donors (mean (SD) release: 45.1pg/mL (7.3) vs 21.2pg/mL (7.3) respectively, p=0.014). Elafin release from HBECs from COPD donors did not change following NTHi infection; however, elafin from healthy donors was significantly reduced (%mean reduction: 23.7%, 95% confidence intervals (CI) of reduction: 5.3-38.4%, p<0.01).
CONCLUSION
CONCLUSIONS
Sputum SLPI and beta defensin-1 may be markers to identify those patients with declining lung function. ICS use was associated with higher sputum osteopontin compared to those with no ICS use.
Identifiants
pubmed: 34093009
doi: 10.2147/COPD.S301622
pii: 301622
pmc: PMC8170372
doi:
Substances chimiques
Pore Forming Cytotoxic Proteins
0
SLPI protein, human
0
Secretory Leukocyte Peptidase Inhibitor
0
beta-Defensins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1437-1447Informations de copyright
© 2021 Cane et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Allergy. 2016 Jan;71(1):58-67
pubmed: 26411293
J Infect Dis. 1994 Feb;169(2):337-42
pubmed: 8106767
J Investig Med. 2000 Sep;48(5):359-66
pubmed: 10979241
Am J Respir Crit Care Med. 2012 Jul 1;186(1):48-55
pubmed: 22447964
Int J Chron Obstruct Pulmon Dis. 2015 Jun 09;10:1075-83
pubmed: 26089657
Am J Respir Crit Care Med. 2012 Dec 1;186(11):1117-24
pubmed: 23024024
Proc Am Thorac Soc. 2007 Oct 1;4(7):535-42
pubmed: 17878466
Chest. 2011 Sep;140(3):611-617
pubmed: 21349930
Exp Lung Res. 2010 Aug;36(6):373-80
pubmed: 20653472
BMC Microbiol. 2015 Nov 14;15:263
pubmed: 26572616
Thorax. 2012 Dec;67(12):1075-80
pubmed: 22863758
Chronic Obstr Pulm Dis. 2020 Oct;7(4):370-381
pubmed: 33108110
Thorax. 2013 Apr;68(4):322-9
pubmed: 23291349
Proc Am Thorac Soc. 2004;1(2):109-14
pubmed: 16113422
Respir Res. 2014 Nov 27;15:151
pubmed: 25427655
Respirology. 2006 Jan;11(1):54-61
pubmed: 16423202
Clin Exp Allergy. 2008 Dec;38(12):1901-10
pubmed: 19037965
Eur Respir J. 2005 Jul;26(1):1-2
pubmed: 15994380
Am J Physiol Lung Cell Mol Physiol. 2000 Jan;278(1):L51-8
pubmed: 10645890
Sci Transl Med. 2019 Aug 28;11(507):
pubmed: 31462509
Eur Respir J. 2004 Jun;23(6):932-46
pubmed: 15219010
Thorax. 2000 Feb;55(2):114-20
pubmed: 10639527
Lancet. 2017 Aug 12;390(10095):659-668
pubmed: 28687413
Mediators Inflamm. 2015;2015:407271
pubmed: 26568662
Eur Respir J. 2016 Feb;47(2):410-9
pubmed: 26828055
Am J Respir Crit Care Med. 2011 Sep 15;184(6):662-71
pubmed: 21680942
Am J Respir Crit Care Med. 2014 Jun 1;189(11):1439-42
pubmed: 24881942
J Leukoc Biol. 1997 Jun;61(6):695-702
pubmed: 9201260
PLoS One. 2019 Sep 17;14(9):e0222449
pubmed: 31527888
PLoS One. 2010 Jan 05;5(1):e8578
pubmed: 20052417
Physiol Rep. 2016 Sep;4(18):
pubmed: 27655795
Nat Commun. 2018 Jun 8;9(1):2229
pubmed: 29884817
J Leukoc Biol. 2011 Aug;90(2):343-56
pubmed: 21551252
Nature. 2002 Jan 24;415(6870):389-95
pubmed: 11807545
Thorax. 2014 Jan;69(1):5-13
pubmed: 23980116
J Allergy Clin Immunol. 2011 Sep;128(3):549-56.e1-12
pubmed: 21752437